Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
His point can be easily summed up with this question,
So you do not think a successful B-UP trial will enhance the valuation of B in a collaboration deal?
That is, it seems, what you are saying. And you would be wrong. The discussion centers around the next deal, not "long term value."
rdunn said:
You obviously do not understand how this agreement works. I (and Waverunner) tried to explain it to you below, I guess to no avail. Here's a simple exercise for you to help drive the point home:
If there were stock issued in the "past week" calculate the price of stock that Aspire would be paying, per the agreement, for that stock. Now compare it to today's price and tell me what you get. The result should be obvious, Aspire would have to be selling at a loss.
It is apparent to me that you still do not realize how the price to Aspire is determined. (Hint: it typically has to do with trading in the previous 12 days).
No, you are the one that needs to read the agreement, Waverunner is spot on. The price Aspire gets is generally figured on the stock prices in the previous 12 trading days, all of which are of course higher than the current price. Aspire would have to be selling at a loss here, which of course they aren't. (to not be selling at a loss they would have to be selling stock issued below $1.13 or so way back when, and we know there was no such issuance).
but that's what you said a few months ago with your early June contest prediction and you were dead wrong. Why should we believe you any more this time? Funny how every single prediction for dates thus far have proven to be embarrassingly wrong. Oops, time for another contest.
LOL, I guess you don't understand what happens on rebalance day. The shares all move today, there's no "methodical dumping over coming weeks."
Amazing the nonsense that is spouted here....FIRE!!!!
If you did a little research you would know it is not possible to be in the Russell 3000 if you can't make the Russell 2000.
Really??? I think you have missed a few beats on that one Karin. Try a search on "Shelly iHub admin". (Same person). An eye opener for sure.
Good thing we didn't bank on it, ROFL.
$1.40 won't happen this year.
what complete and utter bullshit.
right, they completed small animal tox because they knew they would have to repeat it all over again once the new lab is certified. LOL Keep reaching though...
NanoViricides Director Milton Boniuk Purchases 25,000 Shares (NNVC)
Funny, you actually think you know more than a director. LOL
NanoViricides Director Milton Boniuk Purchases 25,000 Shares (NNVC)
I find it amusing that your research has not turned up the most recent data on this so-called "competitor"
ok, I see a more than doubling in performance of NNVC over the DOW for the last 2 yrs (70% vs. 32%):
http://finance.yahoo.com/echarts?s=NNVC+Interactive#%7B%22range%22%3A%222y%22%2C%22scale%22%3A%22linear%22%2C%22comparisons%22%3A%7B%22%5EDJI%22%3A%7B%22color%22%3A%22%23cc0000%22%2C%22weight%22%3A1%7D%7D%7D
right, just like material for tox had to be cGMP and therefore couldn't come from the existing facility. LOL
This has been explained to you about half a dozen times now. Here we go, one last time: They spent most of the year scaling the process to 200g batches, not cobbling together tiny little batches over the course of the year to make a total of 200g. Now that the process has been scaled to 200g, that is the batch size going forward.
I see you very carefully selected your time period for comparison. Try this:
http://finance.yahoo.com/q/ta?s=%5EDJI&t=2y&l=on&z=l&q=l&p=&a=&c=nnvc
(that would be eactly twice the return of the DOW over 2 yrs, 64% vs 32%))
If that were truly the case do you think Dr. Boniuk would really have bought a bunch more shares last month? Insiders only buy for one reason - they are confident the stock price is going higher. I can assure you Boniuk is fully aware of current production capabilities.
Sometimes it pays to use just a modicum of common sense.
that's probably why Dr. Boniuk bought a bunch more shares last month in the open market. You figured it out!
a pipeline of 6 major drug candidates on less than $50 million spent and you are calling that the "most expensive"? That is laughable as it has to be the LEAST expensive pipeline of major drug candidates ever assembled by a biotech drug discovery company.
As far as the slowest, wrong there as well. Development time for successful drugs frequently exceeds 10 yrs.
And no a shelf filing is just that, a filing not a "grab of another $50 million" or any other such transaction. A shelf filing merely authorizes them to raise money as and if needed. Nearly all preclincal biotechs have them in place. At least any prudent management has one in place.
LOL, back to the ol' "they didn't have a control group" line of B.S. It was B.S. when you said it was the case for Dengue as was quickly debunked and is an equivalent load of B.S. this time around as well. Hilarious though rawn.
Yep, only up 9% LOL.
but my top secret sources say he didn't really buy any stock and that is a faked SEC document. Besides, what does a Director know who only has about $12 million invested and is looking for more. LOL
A year to complete Phase I? Sorry but that is way off the mark. More like a month.
of course the issue is that it was 100% lethal in the animal model used where DengueCide saved 50%. But keep chasing down those irrelevant angles.
you said there would be no tox, remember?
your theories seem to clash with reality:
based on how the other ebola stocks are performing today (TKMR down 18%, BCRX down 12%) I would expect NNVC to actually close down today since it was ebola news that jacked it up last week.
Looks like TERMINATOR X is actually the one who called it, ahead of you:
Interesting theory,
Really?
First, I am not a dude. Second, as you can see the charts showed nearly identical performance over 6 months. Third, I believe your interpretation is correct that everything points to only one 200g batch being produced so far. That's why it will be taking up to 18 months to finish preclinical work. And that probably assumes material supplemented from the new facility comes in a timely manner.
it says those trial phases could be COMPLETED by 2016-2017, that's pretty much what we were expecting. And maybe some very good news (and proof of concept) with ebola along the way.
http://finance.yahoo.com/q/bc?s=NNVC&t=6m&l=on&z=l&q=l&c=tkmr
LOL, nice careful crafting of your timeframe. TKMR is a one trick pony that will splat before that trick is finished.
successful ebola drug?? LOL, the drug was halted for safety concerns before the big spread in cases. Feel free to buy their stock though. Good luck.